Skip to main content

Table 2 Secondary outcomes

From: Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease

 

Once-daily

Twice-daily

P Value

mUPDRS

17.5 ± 8.2

17.1 ± 8.9

0.324

Hoehn and Yahr stage

2.1 ± 0.6

2.1 ± 0.6

0.260

Excessive daytime sleepiness

6.3 ± 5.2

6.4 ± 4.8

0.498

Compliance (%)

98.4 ± 3.9

97.6 ± 3.8

0.112

Sleep questionnaire

  Overall quality of sleep

2.9 ± 2.6

3.2 ± 2.5

0.307

  Nocturnal off-symptoms

2.9 ± 3.2

3.1 ± 3.2

0.396

  Early morning off symptoms

2.5 ± 3.3

2.9 ± 3.2

0.384

PGI-I, no (%)

  Overall

32 (52.5)

42 (68.9)

0.078

  Off duration

27 (44.3)

38 (62.3)

0.035a

  Worst wearing-off severity

28 (45.9)

34 (55.7)

0.238

  Dyskinesia duration

13 (21.3)

16 (26.2)

0.549

  Dyskinesia severity

16 (26.2)

15 (24.6)

1.000

  1. a P <0.005.
  2. mUPDRS, Unified Parkinson’s Disease Rating Scale part 3; PGI-I, patient global impressions of improvement.